Results 131 to 140 of about 328,798 (314)

Molecular Docking and Target‐Specific Binding Profiles of Benzosuberane‐Based Compounds

open access: yesChemMedChem, EarlyView.
Benzosuberane represents a promising scaffold in medicinal chemistry. Several benzosuberane‐based derivatives are described in this review as anticancer agents, including antivascular agents, DNA‐intercalators, receptor modulators and kinase inhibitors.
Michail A. Saragatsis   +3 more
wiley   +1 more source

Comparison of irisin hormone expression between thyroid cancer tissues and oncocytic variant cells

open access: yesCancer Management and Research, 2019
Kader Ugur,1 Suleyman Aydin,2 Tuncay Kuloglu,3 Gokhan Artas,4 Mehmet Ali Kocdor,5 İbrahim Sahin,2,6 Meltem Yardim,2 İbrahim Hanefi Ozercan41Department of Endocrinology and Metabolism Disease, School of Medicine, Firat University, Elazig, Turkey ...
Ugur K   +7 more
doaj  

B7-H3 and ICAM-1 are potentially therapeutic targets for thyroid carcinoma

open access: yesDiagnostic Pathology
Although most differentiated thyroid carcinoma has a clinically favorable prognosis, some of specific types of thyroid cancer (such as anaplastic thyroid carcinoma and advanced papillary thyroid carcinoma) show fatal outcomes and require novel treatments.
Pengtao Song, Yongcan Xu, Guochao Ye
doaj   +1 more source

Unusual Presentation of Cystic Papillary Thyroid Carcinoma

open access: yesCase Reports in Endocrinology, 2012
Papillary thyroid carcinoma is the most common thyroid malignancy, accounting for 80% of all thyroid cancers. The most common presentation of thyroid cancer is an asymptomatic thyroid mass or a nodule.
Vijayraj S. Patil   +2 more
doaj   +1 more source

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

open access: yesClinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi   +11 more
wiley   +1 more source

Minimally invasive video-assisted thyroidectomy for the early-stage differential thyroid carcinoma [PDF]

open access: gold, 2012
Jianjun Yu   +15 more
openalex   +1 more source

Quantitative Approaches to Accelerate MASH Drug Discovery and Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Metabolic dysfunction‐associated steatohepatitis (MASH) is a widespread liver condition that leads to cirrhosis, hepatic carcinoma, and increased mortality rates. In MASH, the diagnosis and accelerated approval of drugs are dependent on changes in histological endpoints; full approval requires lengthy outcomes trials.
Yasmeen Abouelhassan   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy